{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:03:47Z","timestamp":1780329827344,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15693"],"award-info":[{"award-number":["22K15693"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Antiseizure medications are often used as preventive treatment of migraine in appropriate cases; however, the efficacy of lacosamide (LCM), a sodium channel blocker, in preventing migraine attacks remains unclear. Cortical spreading depolarization (CSD) refers to a wave of slowly propagating depolarization across the cerebral cortex. CSD animal models have been extensively used to investigate migraine attacks and evaluate the effects of migraine medication. Herein, we examined the effects of single dose LCM (40\u00a0mg\/kg) on CSD sensitivity in a mouse model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Findings<\/jats:title>\n            <jats:p>Thirty-two C57BL\/6 mice (male, <jats:italic>n<\/jats:italic>\u2009=\u200916; female, <jats:italic>n<\/jats:italic>\u2009=\u200916) were intraperitoneally injected with either LCM (40\u00a0mg\/kg) or saline before CSD sensitivity testing. Potassium chloride (KCl) was administered to induce CSD, and the CSD threshold, frequency, and propagation velocity were determined. The average CSD frequency induced by 1\u00a0M KCl was significantly lower (<jats:italic>p<\/jats:italic>\u2009=\u20090.030) and the CSD propagation velocity tended to be lower in the female LCM group than in the saline group. However, no significant differences were observed in any of the three CSD parameters in male mice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In female mice, single dose LCM treatment significantly reduced CSD frequency induced by KCl. Further investigations are warranted to assess the clinical potential of LCM in preventing migraine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10194-025-02099-9","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:56:09Z","timestamp":1752670569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of lacosamide on cortical spreading depolarization in mice"],"prefix":"10.1186","volume":"26","author":[{"given":"Chisato","family":"Iba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Unekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikane","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2099_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495","journal-title":"Lancet"},{"key":"2099_CR2","first-page":"954","volume":"17","author":"GBD","year":"2016","unstructured":"GBD (2016) Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954\u2013976","journal-title":"Lancet Neurol"},{"key":"2099_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s10194-024-01889-x","volume":"25","author":"A Raggi","year":"2024","unstructured":"Raggi A, Leonardi M, Arruda M et al (2024) Hallmarks of primary headache: part 1 - migraine. J Headache Pain 25:189","journal-title":"J Headache Pain"},{"key":"2099_CR4","first-page":"927","volume":"95","author":"E Caronna","year":"2024","unstructured":"Caronna E, Gallardo VJ, Egeo G et al (2024) Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry 95:927\u2013937","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2099_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N et al (2022) Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol 22:512","journal-title":"BMC Neurol"},{"key":"2099_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11940-019-0558-1","volume":"21","author":"SK Parikh","year":"2019","unstructured":"Parikh SK, Silberstein SD (2019) Current status of antiepileptic drugs as preventive migraine therapy. Curr Treat Options Neurol 21:16","journal-title":"Curr Treat Options Neurol"},{"key":"2099_CR7","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1046\/j.1526-4610.2001.01154-4.x","volume":"41","author":"NT Mathew","year":"2001","unstructured":"Mathew NT (2001) Antiepileptic drugs in migraine prevention. Headache 41:S18\u2013S24","journal-title":"Headache"},{"key":"2099_CR8","doi-asserted-by":"publisher","first-page":"333102424130538","DOI":"10.1177\/03331024241305381","volume":"45","author":"R Ornello","year":"2025","unstructured":"Ornello R, Caponnetto V, Ahmed F et al (2025) Evidence-based guidelines for the pharmacological treatment of migraine. Cephalalgia 45:3331024241305381","journal-title":"Cephalalgia"},{"key":"2099_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","volume":"50","author":"P Hal\u00e1sz","year":"2009","unstructured":"Hal\u00e1sz P, K\u00e4lvi\u00e4inen R, Mazurkiewicz-Beldzi\u0144ska M et al (2009) Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 50:443\u2013453","journal-title":"Epilepsia"},{"key":"2099_CR10","unstructured":"Agency E.M. Lacosamide UCB (lacosamide). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lacosamide-ucb-epar-medicine-overview_en.pdf."},{"key":"2099_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-018-0898-3","volume":"19","author":"E Vatzaki","year":"2018","unstructured":"Vatzaki E, Straus S, Dogne JM et al (2018) Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. J Headache Pain 19:68","journal-title":"J Headache Pain"},{"key":"2099_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2023.2247963","volume":"22","author":"W Wells-Gatnik","year":"2023","unstructured":"Wells-Gatnik W, Martelletti P (2023) Antiseizure medications as migraine preventatives: a call for action for a teratogenic and neurodevelopmental risk removal. Expert Opin Drug Saf 22:777\u2013781","journal-title":"Expert Opin Drug Saf"},{"key":"2099_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/epi.17924","volume":"65","author":"P Perucca","year":"2024","unstructured":"Perucca P, Bourikas D, Voinescu PE et al (2024) Lacosamide and pregnancy: data from spontaneous and solicited reports. Epilepsia 65:1275\u20131284","journal-title":"Epilepsia"},{"key":"2099_CR14","doi-asserted-by":"publisher","first-page":"7615","DOI":"10.1038\/s41598-020-64626-9","volume":"10","author":"B L\u00f3pez-Escobar","year":"2020","unstructured":"L\u00f3pez-Escobar B, Fern\u00e1ndez-Torres R, Vargas-L\u00f3pez V et al (2020) Lacosamide intake during pregnancy increases the incidence of foetal malformations and symptoms associated with schizophrenia in the offspring of mice. Sci Rep 10:7615","journal-title":"Sci Rep"},{"key":"2099_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejpain.2005.04.002","volume":"10","author":"T St\u00f6hr","year":"2006","unstructured":"St\u00f6hr T, Krause E, Selve N (2006) Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain 10:241\u2013249","journal-title":"Eur J Pain"},{"key":"2099_CR16","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1097\/PR9.0000000000000565","volume":"1","author":"A Moutal","year":"2016","unstructured":"Moutal A, Eyde N, Telemi E et al (2016) Efficacy of (S)-Lacosamide in preclinical models of cephalic pain. Pain Rep 1:e565","journal-title":"Pain Rep"},{"key":"2099_CR17","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/ejp.820","volume":"20","author":"MC Greco","year":"2016","unstructured":"Greco MC, Capuano A, Navarra P, Tringali G (2016) Lacosamide inhibits calcitonin gene-related peptide production and release at trigeminal level in the rat. Eur J Pain 20:959\u2013966","journal-title":"Eur J Pain"},{"key":"2099_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/head.14367","volume":"62","author":"S Masrour","year":"2022","unstructured":"Masrour S (2022) Lacosamide for refractory trigeminal neuralgia and other facial pain-Case report. Headache 62:1227\u20131230","journal-title":"Headache"},{"key":"2099_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s13760-024-02499-9","volume":"124","author":"S Elgamal","year":"2024","unstructured":"Elgamal S, Ahmed SR, Nahas MM et al (2024) The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial. Acta Neurol Belg 124:965\u2013972","journal-title":"Acta Neurol Belg"},{"key":"2099_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jocn.2015.08.004","volume":"24","author":"DR Kramer","year":"2016","unstructured":"Kramer DR, Fujii T, Ohiorhenuan I, Liu CY (2016) Cortical spreading depolarization: pathophysiology, implications, and future directions. J Clin Neurosci 24:22\u201327","journal-title":"J Clin Neurosci"},{"key":"2099_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/bs.pbr.2020.05.009","volume":"255","author":"T Takizawa","year":"2020","unstructured":"Takizawa T, Ayata C, Chen SP (2020) Therapeutic implications of cortical spreading depression models in migraine. Prog Brain Res 255:29\u201367","journal-title":"Prog Brain Res"},{"key":"2099_CR22","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1073\/pnas.071582498","volume":"98","author":"N Hadjikhani","year":"2001","unstructured":"Hadjikhani N, Sanchez Del Rio M, Wu O et al (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 98:4687\u20134692","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2099_CR23","doi-asserted-by":"publisher","first-page":"11163","DOI":"10.3390\/ijms252011163","volume":"25","author":"E Kitamura","year":"2024","unstructured":"Kitamura E, Imai N (2024) Molecular and cellular neurobiology of spreading depolarization\/depression and migraine: a narrative review. Int J Mol Sci 25:11163","journal-title":"Int J Mol Sci"},{"key":"2099_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrneurol.2013.192","volume":"9","author":"AC Charles","year":"2013","unstructured":"Charles AC, Baca SM (2013) Cortical spreading depression and migraine. Nat Rev Neurol 9:637\u2013644","journal-title":"Nat Rev Neurol"},{"key":"2099_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10194-021-01271-1","volume":"22","author":"O Kursun","year":"2021","unstructured":"Kursun O, Yemisci M, van den Maagdenberg AMJM, Karatas H (2021) Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain 22:55","journal-title":"J Headache Pain"},{"key":"2099_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/ijms24010085","volume":"24","author":"MN Volobueva","year":"2022","unstructured":"Volobueva MN, Suleymanova EM, Smirnova MP, Bolshakov AP, Vinogradova LV (2022) A single episode of cortical spreading depolarization increases mrna levels of proinflammatory cytokines, calcitonin gene-related peptide and pannexin-1 channels in the cerebral Cortex. Int J Mol Sci 24:85","journal-title":"Int J Mol Sci"},{"key":"2099_CR27","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/ana.22329","volume":"69","author":"X Zhang","year":"2011","unstructured":"Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R (2011) Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol 69:855\u2013865","journal-title":"Ann Neurol"},{"key":"2099_CR28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/0271678X19859381","volume":"40","author":"T Takizawa","year":"2020","unstructured":"Takizawa T, Qin T, Lopes de Morais A et al (2020) Non-invasively triggered spreading depolarizations induce a rapid pro-inflammatory response in cerebral cortex. J Cereb Blood Flow Metab 40:1117\u20131131","journal-title":"J Cereb Blood Flow Metab"},{"key":"2099_CR29","doi-asserted-by":"publisher","first-page":"13803","DOI":"10.3390\/ijms232213803","volume":"23","author":"C Iba","year":"2022","unstructured":"Iba C, Unekawa M, Izawa Y, Nakahara J, Takizawa T (2022) Effect of Goreisan, a Japanese traditional medicine, on cortical spreading depolarization in mice. Int J Mol Sci 23:13803","journal-title":"Int J Mol Sci"},{"key":"2099_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s10194-024-01867-3","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Ihara K, Unekawa M et al (2024) Effects of passive smoking on cortical spreading depolarization in male and female mice. J Headache Pain 25:162","journal-title":"J Headache Pain"},{"key":"2099_CR31","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1177\/0333102417738249","volume":"38","author":"M Unekawa","year":"2018","unstructured":"Unekawa M, Ikeda K, Tomita Y et al (2018) Enhanced susceptibility to cortical spreading depression in two types of Na(+), K(+)-ATPase \u03b12 subunit-deficient mice as a model of familial hemiplegic migraine 2. Cephalalgia 38:1515\u20131524","journal-title":"Cephalalgia"},{"key":"2099_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350","journal-title":"Nat Rev Neurol"},{"key":"2099_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183\u2013187","journal-title":"Ann Neurol"},{"key":"2099_CR34","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1517\/13543784.2010.511174","volume":"19","author":"G McCleane","year":"2010","unstructured":"McCleane G (2010) Lacosamide for pain. Expert Opin Investig Drugs 19:1129\u20131134","journal-title":"Expert Opin Investig Drugs"},{"key":"2099_CR35","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1586\/14737175.8.11.1649","volume":"8","author":"V Biton","year":"2008","unstructured":"Biton V (2008) Lacosamide for the treatment of diabetic neuropathic pain. Expert Rev Neurother 8:1649\u20131660","journal-title":"Expert Rev Neurother"},{"key":"2099_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11916-014-0467-7","volume":"19","author":"RJ Storer","year":"2015","unstructured":"Storer RJ, Supronsinchai W, Srikiatkhachorn A (2015) Animal models of chronic migraine. Curr Pain Headache Rep 19:467","journal-title":"Curr Pain Headache Rep"},{"key":"2099_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/fcp.12598","volume":"35","author":"L Lazzarotto","year":"2021","unstructured":"Lazzarotto L, Pfl\u00fcger P, Regner GG et al (2021) Lacosamide improves biochemical, genotoxic, and mitochondrial parameters after PTZ-kindling model in mice. Fundam Clin Pharmacol 35:351\u2013363","journal-title":"Fundam Clin Pharmacol"},{"key":"2099_CR38","unstructured":"Current Review in clinical science -Summary of Antiepileptic Drugs Available in the United States of America, A.E. Society, Editor. 2018."},{"key":"2099_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000117004","volume":"34","author":"H Kaube","year":"1994","unstructured":"Kaube H, Goadsby PJ (1994) Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur Neurol 34:30\u201335","journal-title":"Eur Neurol"},{"key":"2099_CR40","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ana.20778","volume":"59","author":"C Ayata","year":"2006","unstructured":"Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59:652\u2013661","journal-title":"Ann Neurol"},{"key":"2099_CR41","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/0333102410388433","volume":"31","author":"U Hoffmann","year":"2011","unstructured":"Hoffmann U, Dilek\u00f6z E, Kudo C, Ayata C (2011) Oxcarbazepine does not suppress cortical spreading depression. Cephalalgia 31:537\u2013542","journal-title":"Cephalalgia"},{"key":"2099_CR42","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.nbd.2010.10.014","volume":"41","author":"VB Bogdanov","year":"2011","unstructured":"Bogdanov VB, Multon S, Chauvel V et al (2011) Migraine preventive drugs differentially affect cortical spreading depression in rat. Neurobiol Dis 41:430\u2013435","journal-title":"Neurobiol Dis"},{"key":"2099_CR43","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/01.wnr.0000175250.33159.a9","volume":"16","author":"S Akerman","year":"2005","unstructured":"Akerman S, Goadsby PJ (2005) Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. NeuroReport 16:1383\u20131387","journal-title":"NeuroReport"},{"key":"2099_CR44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1177\/0333102412444015","volume":"32","author":"M Unekawa","year":"2012","unstructured":"Unekawa M, Tomita Y, Toriumi H, Suzuki N (2012) Suppressive effect of chronic peroral topiramate on potassium-induced cortical spreading depression in rats. Cephalalgia 32:518\u2013527","journal-title":"Cephalalgia"},{"key":"2099_CR45","doi-asserted-by":"publisher","first-page":"18985","DOI":"10.1073\/pnas.1215435109","volume":"109","author":"A Tozzi","year":"2012","unstructured":"Tozzi A, de Iure A, Di Filippo M et al (2012) Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci U S A 109:18985\u201318990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2099_CR46","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/jcbfm.2010.92","volume":"30","author":"U Hoffmann","year":"2010","unstructured":"Hoffmann U, Dilek\u00f6z E, Kudo C, Ayata C (2010) Gabapentin suppresses cortical spreading depression susceptibility. J Cereb Blood Flow Metab 30:1588\u20131592","journal-title":"J Cereb Blood Flow Metab"},{"key":"2099_CR47","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/glia.22853","volume":"63","author":"X Yao","year":"2015","unstructured":"Yao X, Smith AJ, Jin BJ, Zador Z, Manley GT, Verkman AS (2015) Aquaporin-4 regulates the velocity and frequency of cortical spreading depression in mice. Glia 63:1860\u20131869","journal-title":"Glia"},{"key":"2099_CR48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ana.21138","volume":"61","author":"KC Brennan","year":"2007","unstructured":"Brennan KC, Romero Reyes M, L\u00f3pez Vald\u00e9s HE, Arnold AP, Charles AC (2007) Reduced threshold for cortical spreading depression in female mice. Ann Neurol 61:603\u2013606","journal-title":"Ann Neurol"},{"key":"2099_CR49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.expneurol.2012.05.002","volume":"236","author":"V Chauvel","year":"2012","unstructured":"Chauvel V, Vamos E, Pardutz A, Vecsei L, Schoenen J, Multon S (2012) Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. Exp Neurol 236:207\u2013214","journal-title":"Exp Neurol"},{"key":"2099_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s10194-023-01598-x","volume":"24","author":"C Kudo","year":"2023","unstructured":"Kudo C, Harriott AM, Moskowitz MA, Waeber C, Ayata C (2023) Estrogen modulation of cortical spreading depression. J Headache Pain 24:62","journal-title":"J Headache Pain"},{"key":"2099_CR51","doi-asserted-by":"publisher","first-page":"16959","DOI":"10.1038\/s41598-018-35285-8","volume":"8","author":"L Kros","year":"2018","unstructured":"Kros L, Lykke-Hartmann K, Khodakhah K (2018) Increased susceptibility to cortical spreading depression and epileptiform activity in a mouse model for FHM2. Sci Rep 8:16959","journal-title":"Sci Rep"},{"key":"2099_CR52","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s12035-014-8775-9","volume":"51","author":"SM Wilson","year":"2015","unstructured":"Wilson SM, Khanna R (2015) Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide. Mol Neurobiol 51:599\u2013609","journal-title":"Mol Neurobiol"},{"key":"2099_CR53","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/jnnp.2005.063750","volume":"76","author":"C Lampl","year":"2005","unstructured":"Lampl C, Katsarava Z, Diener HC, Limmroth V (2005) Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 76:1730\u20131732","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2099_CR54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11916-018-0735-z","volume":"22","author":"A Vgontzas","year":"2018","unstructured":"Vgontzas A, Burch R (2018) Episodic migraine with and without aura: key differences and implications for pathophysiology, management, and assessing risks. Curr Pain Headache Rep 22:78","journal-title":"Curr Pain Headache Rep"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02099-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02099-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02099-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:52:09Z","timestamp":1757253129000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02099-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2099"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02099-9","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the experimental procedures were approved by the Keio University Institutional Animal Care and Use Committee (authorization no. A2021-006) and were performed in accordance with the university\u2019s guidelines and the Animal Research: Reporting In Vivo Experiments (ARRIVE) reporting guidelines for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: TT is a consultant\/advisor and\/or serves on an advisory board for Eli Lilly, Otsuka, Amgen, Pfizer, and Teijin and has received speaker honoraria from Daiichi Sankyo, Eli Lilly, Otsuka, Amgen, Sawai, UCB Japan, Kowa, Kyowa Kirin, Eisai, Takeda, and Santen Pharmaceutical and grant\/funding from Eli Lilly, Pfizer, and Tsumura outside the submitted work. JN has received honoraria from Amgen, Novartis, and Daiichi Sankyo.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}